376 related articles for article (PubMed ID: 24703906)
21. Breakpoint heterogeneity in (2;3)(p15-23;q26) translocations involving EVI1 in myeloid hemopathies.
De Braekeleer M; Guéganic N; Tous C; Le Bris MJ; Basinko A; Morel F; Douet-Guilbert N
Blood Cells Mol Dis; 2015 Feb; 54(2):160-3. PubMed ID: 25486926
[TBL] [Abstract][Full Text] [Related]
22. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.
De Braekeleer M; Le Bris MJ; De Braekeleer E; Basinko A; Morel F; Douet-Guilbert N
Future Oncol; 2015; 11(11):1675-86. PubMed ID: 26043219
[TBL] [Abstract][Full Text] [Related]
23. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.
Morishita K; Parganas E; William CL; Whittaker MH; Drabkin H; Oval J; Taetle R; Valentine MB; Ihle JN
Proc Natl Acad Sci U S A; 1992 May; 89(9):3937-41. PubMed ID: 1570317
[TBL] [Abstract][Full Text] [Related]
24. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.
Mochizuki N; Shimizu S; Nagasawa T; Tanaka H; Taniwaki M; Yokota J; Morishita K
Blood; 2000 Nov; 96(9):3209-14. PubMed ID: 11050005
[TBL] [Abstract][Full Text] [Related]
25. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26).
Suzukawa K; Taki T; Abe T; Asoh H; Kamada N; Yokota J; Morishita K
Genomics; 1997 Jun; 42(2):356-60. PubMed ID: 9192861
[TBL] [Abstract][Full Text] [Related]
26. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome.
Levy ER; Parganas E; Morishita K; Fichelson S; James L; Oscier D; Gisselbrecht S; Ihle JN; Buckle VJ
Blood; 1994 Mar; 83(5):1348-54. PubMed ID: 8118036
[TBL] [Abstract][Full Text] [Related]
27. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
28. Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
[TBL] [Abstract][Full Text] [Related]
29. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia.
Pekarsky Y; Rynditch A; Wieser R; Fonatsch C; Gardiner K
Cancer Res; 1997 Sep; 57(18):3914-9. PubMed ID: 9307271
[TBL] [Abstract][Full Text] [Related]
30. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
Hinai AA; Valk PJ
Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
[TBL] [Abstract][Full Text] [Related]
31. Acute panmyelosis with myelofibrosis with EVI1 amplification.
Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
[TBL] [Abstract][Full Text] [Related]
32. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.
Martinelli G; Ottaviani E; Buonamici S; Isidori A; Borsaru G; Visani G; Piccaluga PP; Malagola M; Testoni N; Rondoni M; Nucifora G; Tura S; Baccarani M
Haematologica; 2003 Nov; 88(11):1221-8. PubMed ID: 14607750
[TBL] [Abstract][Full Text] [Related]
33. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
34. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
35. The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.
Shen C; Chen MT; Zhang XH; Yin XL; Ning HM; Su R; Lin HS; Song L; Wang F; Ma YN; Zhao HL; Yu J; Zhang JW
PLoS Genet; 2016 Sep; 12(9):e1006259. PubMed ID: 27617961
[TBL] [Abstract][Full Text] [Related]
36. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
[TBL] [Abstract][Full Text] [Related]
37. Expression of EVI1 and the Retinoblastoma genes in acute myelogenous leukemia with t(3;13)(q26;q13-14).
Yufu Y; Sadamura S; Ishikura H; Abe Y; Katsuno M; Nishimura J; Nawata H
Am J Hematol; 1996 Sep; 53(1):30-4. PubMed ID: 8813093
[TBL] [Abstract][Full Text] [Related]
38. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
[TBL] [Abstract][Full Text] [Related]
39. EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
[TBL] [Abstract][Full Text] [Related]
40. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
